Cannovation Clinical Research Partners
Clinical research consulting firm focused on development, regulatory strategy, clinical trials, manufacturing support, and commercialization for cannabinoid- and psychedelic-based therapeutics and related products. Services include preclinical and clinical trial support (Phases I–IV), regulatory guidance (including DEA/NIH pathways), GMP/QA/QC support, material sourcing and supply chain strategy, and market-entry/commercialization planning.
Industries
Nr. of Employees
small (1-50)
Cannovation Clinical Research Partners
Products
Psychedelic Legal Strategy
A service designed to guide organizations through the complex and evolving legal landscape surrounding psychedelics, supporting clients in navigating global and U.S.-specific legal challenges to accelerate the development and commercialization of psychedelic-based therapeutics.
Psychedelic Legal Strategy
A service designed to guide organizations through the complex and evolving legal landscape surrounding psychedelics, supporting clients in navigating global and U.S.-specific legal challenges to accelerate the development and commercialization of psychedelic-based therapeutics.
Services
Strategic planning for research, development and commercialization including landscape analysis, competitive intelligence and project roadmaps.
Execution support for R&D plans including preclinical study coordination, program management and technical oversight.
Regulatory and legal strategy focused on controlled-substance and cannabinoid/psychedelic programs, including interactions with DEA and other agencies.
Material sourcing, supplier identification, manufacturing process optimization and regulatory compliance guidance for product manufacture.
Supply chain design and packaging strategy to support regulatory requirements and commercial distribution.
Support to implement and maintain GMP-compliant quality systems, QC testing workflows and product release processes.
Strategic planning for research, development and commercialization including landscape analysis, competitive intelligence and project roadmaps.
Execution support for R&D plans including preclinical study coordination, program management and technical oversight.
Regulatory and legal strategy focused on controlled-substance and cannabinoid/psychedelic programs, including interactions with DEA and other agencies.
Material sourcing, supplier identification, manufacturing process optimization and regulatory compliance guidance for product manufacture.
Supply chain design and packaging strategy to support regulatory requirements and commercial distribution.
Support to implement and maintain GMP-compliant quality systems, QC testing workflows and product release processes.
Expertise Areas
- Clinical trial management (Phases I–IV)
- Cannabinoid therapeutics development
- Psychedelic drug development
- Regulatory compliance (DEA, FDA, NIH)
Key Technologies
- Clinical trial design and operations
- Multicenter trial management
- Pharmacokinetics/pharmacodynamics studies
- Analytical chemistry and assay development
News & Updates
Announcement of organizational changes including formation of three service divisions (traditional drug development, psychedelics, cannabis-derived therapeutics) and appointment of a Chief Scientific Officer to lead preclinical and clinical services.
Overview of psychedelic-assisted therapies, mechanisms of action, therapeutic applications, legal/ethical considerations and future directions.
Press announcement of company launch and description of services spanning preclinical research, clinical trials and U.S. commercialization for cannabinoid therapeutics.
Announcement of organizational changes including formation of three service divisions (traditional drug development, psychedelics, cannabis-derived therapeutics) and appointment of a Chief Scientific Officer to lead preclinical and clinical services.
Overview of psychedelic-assisted therapies, mechanisms of action, therapeutic applications, legal/ethical considerations and future directions.
Press announcement of company launch and description of services spanning preclinical research, clinical trials and U.S. commercialization for cannabinoid therapeutics.